Untitled case

I'll research this case thoroughly before drafting. Let me start with several searches.

This is clearly the Merck sitagliptin ANDA litigation. Let me dig deeper into the specific case and its IPR history.

Let me verify the specific disposition of this case and the patents asserted.

Case Overview: Merck Sharp & Dohme Corp. v. Aurobindo Pharma, Ltd. et al., No. 1:20-cv-01099-RGA (D. Del.)

Parties and their roles. This is a classic Hatch-Waxman (ANDA) patent case, not an NPE/PAE assertion. The plaintiff is Merck Sharp & Dohme Corp. (now Merck Sharp & Dohme LLC), a New Jersey operating company and subsidiary of Merck & Co., Inc., the brand manufacturer of the sitagliptin franchise — JANUVIA® (sitagliptin phosphate), JANUMET® and JANUMET® XR (sitagliptin phosphate + metformin HCl). The defendants are Aurobindo Pharma Limited (India) and Aurobindo Pharma USA, Inc. (a Delaware corporation with a registered agent, which is why venue was pleaded in Delaware), generic-drug manufacturers. The complaint was filed August 21, 2020 and assigned to Judge Richard G. Andrews; the docket's Rule 7.1 disclosure confirms Merck & Co., Inc. as the parent, and the Report to the Commissioner identifies U.S. Patent No. 7,326,708 as the patent at issue (D.I. 4). The case is a member action of the consolidated In re Sitagliptin Phosphate ('708 & '921) Patent Litigation, No. 1:19-md-02902-RGA (D. Del.), which centralized Merck's roughly fourteen parallel generic suits.

Accused product and patents. The accused instrumentalities are Aurobindo's ANDA products — generic versions of Merck's sitagliptin-containing diabetes drugs (sitagliptin phosphate alone, and the sitagliptin + metformin fixed-dose combination). Merck treated Aurobindo's Paragraph IV certifications — that the '708 patent is invalid, unenforceable, or not infringed — as statutory acts of infringement under 35 U.S.C. § 271(e)(2), and sought injunctive relief barring launch before expiration (contemporaneous trade-press coverage, e.g., Express Pharma/PTI, Aug. 2020, describes the suit as reaching Aurobindo's proposed generic JANUMET). The asserted patent, U.S. 7,326,708, "Phosphoric Acid Salt of a Dipeptidyl Peptidase-IV Inhibitor" (filed June 23, 2004; issued Feb. 5, 2008; assigned to Merck), claims the 1:1 dihydrogenphosphate (DHP) salt of sitagliptin, its (R)- and (S)-enantiomers, the crystalline monohydrate form, and methods of treating Type 2 diabetes — a salt-form/"polymorph-type" patent layered on top of Merck's earlier sitagliptin compound patent (U.S. 6,699,871 / WO 2003/004498, "Edmondson"). The companion '921 patent (U.S. 8,414,921), covering the sitagliptin-plus-metformin formulation, was also at issue across the MDL; the metadata here lists only the '708. Caveat: I could not independently confirm from a primary docket source which additional patents (if any) were pleaded in the four counts of this particular '1099 action beyond the '708 identified in the Report to the Commissioner.

Procedural posture, venue, and why it matters. The District of Delaware is the leading venue for ANDA/Paragraph IV litigation because of its specialized patent bench, its default discovery standards, and its concentration of branded-pharma local counsel, and this case was folded into a coordinated MDL before Judge Andrews — a significant efficiency lever given the dozen-plus parallel defendants. The case is closed: the Unified Patents litigation portal records a termination date of September 30, 2021 ("CASE CLOSED per D.I. 133"), consistent with the wave of stipulated consent judgments and settlements that disposed of most of the MDL members (Merck's settlements permitted generic JANUVIA/JANUMET entry in May 2026 and JANUMET XR in July 2026, or earlier under certain circumstances, per Merck's Sept. 22, 2022 press release). I could not confirm the exact instrument terminating D.I. 133 from a primary source, so the specific basis (consent judgment versus stipulation of dismissal) should be verified on PACER. The case is notable for its IPR linkage: the '708 patent was challenged in IPR2020-00040 (Mylan Pharmaceuticals v. Merck), with Dr. Reddy's and Sun Pharmaceuticals joined via IPR2020-01060 and IPR2020-01072. The Board's Final Written Decision (May 7, 2021) held no challenged claims unpatentable (rejecting anticipation by Edmondson and obviousness over Edmondson/Bastin/Brittain), and the Federal Circuit affirmed in Mylan Pharmaceuticals Inc. v. Merck Sharp & Dohme Corp., No. 2021-2121 (Fed. Cir. Sept. 29, 2022) — the decision that produced the widely cited "957 salts" holding on the In re Petering "at once envisage" standard. The PTAB certificate issued September 19, 2023, confirming patentability of claims 1–4 and others. Commercially, the patent protects a blockbuster franchise — JANUMET generated over $2 billion globally, including ~$589 million in U.S. sales in 2019 — and the '708 patent, with pediatric exclusivity, runs to May 24, 2027, making these suits central to when low-cost generic sitagliptin reached the U.S. market. A follow-on Aurobindo action was filed in 2025 (No. 1:25-cv-00449-CFC, Judge Connolly) over a JANUMET XR ANDA, again asserting the '708 patent.

Sourcing note: Party identities, filing date, judge, patent number, and the MDL/IPR framework are corroborated by the Justia/CourtListener docket entries, the Unified Patents case page, PTAB papers (IPR2020-00040 FWD; Teva's IPR2020-01045 mandatory notices), the Federal Circuit's Mylan v. Merck opinion, and Merck's press materials. The precise disposition document for this individual docket (D.I. 133) is the one item I could not verify to primary-source depth, and the scope of asserted patents/claims in this specific '1099 action (versus the MDL generally) rests on the complaint's Report to the Commissioner rather than the full pleading.

Merck Sharp & Dohme Corp. v. Aurobindo Pharma Ltd., No. 1:20-cv-01099-RGA (D. Del.)

Bottom line: This was one ANDA/Paragraph IV suit in Merck's sprawling sitagliptin-phosphate litigation campaign over U.S. Patent No. 7,326,708 (the "’708 patent," Phosphoric Acid Salt of a Dipeptidyl Peptidase-IV Inhibitor — the crystalline sitagliptin dihydrogenphosphate salt in JANUVIA®/JANUMET®/JANUMET XR®). It was filed 2020-08-21, assigned to Judge Richard G. Andrews, and closed on 2021-09-30 — during expert discovery, weeks before a scheduled invalidity pretrial conference, and while the parallel PTAB proceedings on the ’708 patent were pending. It never reached trial, and no claim-construction opinion or merits judgment issued in this docket.

---

1. Parties, product, and procedural setting

The ’708 patent issued 2008-02-05, claims a dihydrogenphosphate salt of sitagliptin (and hydrates), with dependent claims to the (R)- and (S)-configurations and the crystalline monohydrate. Orange-Book-listed against JANUVIA, JANUMET, and JANUMET XR.

Critically, this was a tag-along case. Merck had filed the anchor sitagliptin Hatch-Waxman suits against ~14 generics in early 2019, and those were consolidated for pretrial proceedings in In re Sitagliptin Phosphate (’708 & ’921) Patent Litigation, No. 19-md-2902-RGA (D. Del.). This 2020 case and its sibling Merck v. Aurobindo, No. 1:20-cv-00949-RGA (filed 2020-07-15) were both "Associated Cases" of the MDL — nearly every scheduling order in this docket was entered jointly across 19-md-2902, 20-cv-949, and 20-cv-1099. That procedural fact matters: most substantive rulings on the ’708 patent were made in the MDL umbrella docket, not in 20-cv-1099 individually.

2. Filing and initial pleadings

• 2020-08-21 — Complaint (D.I. 1). Filed with jury demand against both Aurobindo entities; Rule 7.1 disclosure and Report to the Commissioner of Patents identifying only the ’708 patent (D.I. 3–4). The complaint pleaded LDO/venue on Aurobindo Pharma USA's Delaware incorporation and Aurobindo's prior litigation conduct in the district.
• 2020-08-27 — Stipulated extension (D.I. 7), So Ordered, resetting the answer deadline to 2020-09-28.
• On or about 2020-09-28 — Aurobindo's Answer, Affirmative Defenses, and Counterclaims (D.I. 8). Aurobindo counterclaimed for **declaratory judgment of invalidity of

I'll start by identifying the case and its parties.

I've identified the case as Merck Sharp & Dohme Corp. v. Aurobindo Pharma, Ltd. et al. Now let me pin down the plaintiff's counsel of record.

Now let me confirm the complaint's signature block and the roles/firms for each attorney.

Case identification (correcting the metadata gap)

The public docket for 1:20-cv-01099 (D. Del.) is:

Merck Sharp & Dohme Corp. v. Aurobindo Pharma, Ltd. and Aurobindo Pharma USA Inc., No. 1:20-cv-01099-RGA (D. Del., filed Aug. 21, 2020) (Judge Richard G. Andrews). ANDA/Hatch‑Waxman action on U.S. Patent No. 7,326,708 (sitagliptin dihydrogenphosphate salt; JANUVIA/JANUMET). Filed as part of the coordinated In re Sitagliptin Phosphate ('708 & '921) Patent Litigation, MDL No. 19-2902-RGA family; docket closed Sept. 30, 2021 (Unified Patents litigation panel; Docket Alarm/Justia dockets; UniCourt case page).

• Plain docket summary: https://dockets.justia.com/docket/delaware/dedce/1:2020cv01099/72974
• Unified Patents panel: https://portal.unifiedpatents.com/litigation/Delaware%20District%20Court/case/1:20-cv-01099

Sole plaintiff / counterclaim-defendant: Merck Sharp & Dohme Corp. (Rule 7.1 parent: Merck & Co., Inc. — D.I. 5). Defendants: Aurobindo Pharma, Ltd. and Aurobindo Pharma USA Inc. (defense counsel of record: Neal C. Belgam / Eve H. Ormerod, Smith Katzenstein & Jenkins, Wilmington; PHV Steven J. Moore and James E. Nealon, both of whom are associated with the Aurobindo side — D.I. 20, Oct. 8, 2020).

Merck's representation was a two-tier structure typical of D. Del.: a Delaware firm (McCarter & English, LLP, Wilmington) appearing on all filings under Local Rule 83.5(d), plus a Washington, D.C. litigation firm (Williams & Connolly LLP) appearing pro hac vice as the merits/trial team.

---

Counsel of record for the plaintiff (Merck Sharp & Dohme Corp.)

Delaware counsel of record — McCarter & English, LLP (Renaissance Centre, 405 N. King St., 8th Fl., Wilmington, DE 19801)

*The Sept. 28, 2020 pro hac vice motion (D.I. 11) was signed by Daniel M. Silver, confirming McCarter is the sponsoring Delaware firm.

Merits/trial counsel appearing pro hac vice — Williams & Connolly LLP (then 725 Twelfth St. NW, Washington, DC 20005; now 680 Maine Ave. SW)

Admitted by the Court's Sept. 28, 2020 order on Merck's motion (D.I. 11; the earlier-signed order is dated 9/28/2020, and PHV registration notices entered Sept. 29, 2020 (Genderson) and Oct. 2, 2020 (Zolan)):

Additional pro hac vice appearances for Merck later in the case (same coordinated docket)

These were granted in this case via joint, multi-case PHV motions; the sources I have do not confirm each attorney's firm:

---

Caveats and sourcing notes

• No in-house counsel appears of record in this docket; Merck's appearances are outside counsel only. Nothing in the public docket indicates Merck filed the complaint pro se or through in-house counsel.
• Counsel are recorded in this case primarily through pro hac vice motions/orders (D.I. 11 and the later PHV motions) and the Sept. 28, 2020 SO ORDERED entry, rather than individual notices of appearance. Individual notices of appearance by the W&C attorneys for this specific docket number were not visible in the sources I could retrieve; PACER would confirm each attorney's formal entry.
• Sealed material: Merck filed sealed service notices/subpoena notices in this case (D.I. 13, 14 and later sealed filings in the Nov. 2020 period), and the related MDL pretrial materials were filed under seal/redacted. Those do not affect who is counsel of record, but they do limit visibility into some activity.
• Role labels: The docket itself does not designate "lead" vs. "of counsel." My assignments of "lead trial counsel" (Genderson), "principal counsel" (Fisher), and "Delaware/local counsel" (Silver) reflect filing order, PHV sponsorship, and contemporaneous reporting (World IP Review's ranking entry for Merck Sharp & Dohme v. Aurobindo Pharma) — they are characterizations, not formal docket designations. The W&C/WIPR entry notes W&C attorneys David Krinsky, Sarah Harris, Shaun Mahaffy and Stanley Fisher on the Merck/Aurobindo matter; Krinsky and Harris appear in the related sugammadex PTE appeal rather than this '708 docket, so I have not listed them as counsel of record here.
• I did not find any attorney listed for Merck in this case whose name I could not tie to a docket entry; where firm affiliation is unconfirmed (Baumgarten, Komis, Uribe, Omoroghomwan), I have said so rather than guess.

I'll research this case, starting with identifying the parties and then the counsel.

The case is Merck Sharp & Dohme Corp. v. Aurobindo Pharma, Ltd. et al., No. 1:20-cv-01099-RGA. Let me find the docket and defense counsel appearances.

Let me get the actual docket entries and identify defense counsel appearances.